ILMN (Illumina) Current Accrued Expense: $157 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ILMN Illumina Inc ILMN
71 GF Score
Price $203.01
GF Value $132.42
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Illumina Current Accrued Expense?

Illumina ILMN +2.45% 71 Current Accrued Expense is $157 Mil as of Jun. 2026. GuruFocus rates ILMN with a GF Score™ of 71/100 and a GF Value™ of $132.42 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Illumina's Current Accrued Expense for the quarter that ended in Jun. 2026 was $157 Mil.

Illumina's quarterly Current Accrued Expense increased from Dec. 2025 ($142 Mil) to Mar. 2026 ($203 Mil) but then declined from Mar. 2026 ($203 Mil) to Jun. 2026 ($157 Mil).

Illumina's annual Current Accrued Expense declined from Dec. 2023 ($685 Mil) to Dec. 2024 ($135 Mil) but then increased from Dec. 2024 ($135 Mil) to Dec. 2025 ($142 Mil).

Illumina Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Illumina's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina Current Accrued Expense Chart

Illumina Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 117.00 626.00 685.00 135.00 142.00

Illumina Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 147.00 118.00 142.00 203.00 157.00
ILMN
71GF Score
Illumina Inc ILMN
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Illumina Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $157 Mil mean?
Illumina (ILMN) has a Current Accrued Expense of $157 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Illumina and its competitors.
Is Illumina's Current Accrued Expense too high?
Illumina's current Current Accrued Expense is $157 Mil. Overall, Illumina has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Illumina's Current Accrued Expense compare to MTD and DGX?
Illumina's Current Accrued Expense of $157 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Diagnostics & Research company?
A good Current Accrued Expense depends on the Medical Diagnostics & Research industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Illumina and its competitors. Illumina's current Current Accrued Expense is $157 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Based on GuruFocus' analysis, Illumina (ILMN) is currently considered Significantly Overvalued. The stock's GF Value™ is $132.42, compared to a current price of $203.01 — trading 53.3% above its estimated fair value. The current Current Accrued Expense is $157 Mil. Illumina's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Illumina (ILMN), the current Current Accrued Expense is $157 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Illumina (ILMN) Overvalued in 2026?

Based on GuruFocus' analysis, Illumina stock appears to be overvalued. The current stock price of $203.01 is trading 53.3% above its estimated GF Value™ of $132.42. GuruFocus considers Illumina to be Significantly Overvalued.

Key valuation signals for ILMN:

  • Current Accrued Expense: $157 Mil
  • GF Value™: $132.42 vs. price of $203.01 (53.3% above fair value)
  • GF Score™: 71/100 with 7 warning signs

No single metric tells the full story. See the ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Illumina Business Description

Address 5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
71GF Score

Get the complete analysis for ILMN

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$203.01
Price
$132.42
GF Value